Activity Description and Educational Objectives

In this Master Class and Practicum, based on a live symposium held at the American Urological Association's 2017 Annual Meeting (AUA 2017), a panel of urology and oncology experts provides guidance on management of prostate cancer in the context of an evolving evidence base and treatment landscape. Most recent therapeutic advances and key clinical trials in early-stage and advanced prostate cancer are reviewed. Additionally, nuances of developing individualized treatment plans are discussed, supplemented by illustrative cases highlighting optimal patient evaluation as well as selection and sequencing of therapies throughout the continuum of the disease, including node-positive, PSA-only, newly diagnosed metastatic, and metastatic castration-resistant prostate cancer scenarios.

Upon completion of this activity, participants should be better able to:

• Assess evidence from clinical trials on hormone, cytotoxic, immunologic, bone-directed, and other novel therapies and combinations for early-stage and advanced prostate cancer
• Describe latest guidelines and consensus recommendations for selection and sequencing of different therapies in the management of patients with early-stage and advanced prostate cancer
• Develop individualized, evidence-based treatment plans for patients with prostate cancer throughout the disease continuum

Target Audience

This activity has been designed to meet the educational needs of urologists and other clinicians involved in the management of prostate cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: June 27, 2017 - June 26, 2018
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Robert Dreicer, MD, MS, MACP, FASCO
Section Head Medical Oncology
Deputy Director, University of Virginia Cancer Center
Associate Director for Clinical Research
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Robert Dreicer, MD, MS, MACP, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant for Asana BioSciences, LLC.; Astellas Pharma US, Inc.; AstraZeneca; Bristol-Myers Squibb; Eisai Inc.; EMD Serono, Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd.; Genentech, Inc.; Medivation, Inc.; Orion; and Sanofi.
Grant/Research Support from Asana BioSciences, LLC.; Bristol-Myers Squibb; Genentech, Inc.; and Lilly.

Faculty

Judd W. Moul, MD, FACS
James H. Semans, MD Professor of Surgery
Division of Urologic Surgery
Director, Duke Prostate Center
Duke University Medical Center
Durham, North Carolina

Judd W. Moul, MD, FACS, has a financial interest/relationship or affiliation in the form of:
Consultant for AbbVie; Blue Earth Diagnostics; and Theralogix.
Grant/Research Support from Astellas Pharma, Inc. and Medivation, Inc.
Speakers Bureau participant with Bayer Corporation; Dendreon Corporation; Ferring Pharmaceuticals; GenomeDx; Genomic Health; Janssen Pharmaceuticals, Inc.; and Sanofi.

William K. Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute
New York, New York

William K. Oh, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Astellas Pharma Inc.; AstraZeneca; Bayer Corporation; Churchill Pharmaceuticals; Inovio Pharmaceuticals, Inc.; Janssen; Remedica; and Sanofi.
Shareholder in Checkpoint Therapeutics, Inc.

Fred Saad, MD, FRCS
Professor and Chief of Urology
Director of Genitourinary Oncology
U of M Endowed Chair in Prostate Cancer Research
University of Montreal Hospital Center (CHUM)
Montreal, Quebec, Canada

Fred Saad, MD, FRCS, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen Inc.; Astellas; Bayer; Janssen; and Sanofi.
Grant/Research Support from Bayer; Janssen; and Sanofi.

Medical Director

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6130-18-T.

Providership

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by independent educational grants from AbbVie, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Sanofi Genzyme.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Copyright © 2000-2017, PeerView Press